A Phase I/II Study to Evaluate the Safety Pharmacodynamics and Efficacy of Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

Overview

The purpose of this study is to identify the best dose of entinostat when combined with bevacizumab and atezolizumab and to find out what side effects are caused by the combination of these drugs in patients with renal cell carcinoma.

Description

The purpose of this study is to identify the best dose of entiostat when combined with bevacizumab and atezolizumab and to find out what side effects are caused by the combination of these drugs in patients with renal cell carcinoma.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions: renal cell carcinoma
  • Age: Between 18 Years - 100 Years
  • Gender: Male or Female
Updated on 20 Nov 2022 . Study ID: TX7389
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center